Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
Akero Therapeutics, Inc. (AKRO) had Debt to Capital Ratio of 0.05 for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-252.06M |
|
-- |
|
-- |
|
$285.42M |
|
$-285.42M |
|
$33.36M |
|
$-252.06M |
|
$-252.06M |
|
$-252.06M |
|
$-252.06M |
|
$-252.06M |
|
$-252.06M |
|
$-285.42M |
|
$-297.92M |
|
67.14M |
|
67.14M |
|
$-3.75 |
|
$-3.75 |
|
| Balance Sheet Financials | |
$770.38M |
|
-- |
|
$55.51M |
|
$825.89M |
|
$39.75M |
|
$35.49M |
|
$36.02M |
|
$75.77M |
|
$750.11M |
|
$750.11M |
|
$750.11M |
|
72.38M |
|
| Cash Flow Statement Financials | |
$-230.11M |
|
$-109.71M |
|
$445.85M |
|
$234.21M |
|
$340.24M |
|
$106.03M |
|
$29.70M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
19.38 |
|
-- |
|
-- |
|
|
Debt to Capital Ratio |
0.05 |
0.05 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-230.11M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-33.60% |
|
-33.60% |
|
-30.52% |
|
-32.08% |
|
$10.36 |
|
$-3.43 |
|
$-3.43 |
|